Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04547712
Recruitment Status : Recruiting
First Posted : September 14, 2020
Last Update Posted : May 5, 2021
Sponsor:
Information provided by (Responsible Party):
MedtronicNeuro

Brief Summary:
The purpose of the study is to demonstrate the safety and effectiveness of adaptive DBS (aDBS) for Parkinson's disease.

Condition or disease Intervention/treatment Phase
Parkinson Disease Device: Adaptive DBS Not Applicable

Detailed Description:
Prospective single-blind, randomized crossover, multi-center study of aDBS in subjects with Parkinson's disease.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Randomization to a crossover sequence of aDBS single threshold and aDBS dual threshold modes
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease
Actual Study Start Date : December 14, 2020
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : July 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: aDBS Single Threshold
Adaptive DBS Single Threshold Mode
Device: Adaptive DBS
Subjects for whom both aDBS modes are acceptable will receive Dual and Single Threshold aDBS
Other Name: aDBS

Experimental: aDBS Dual Threshold
Adaptive DBS DualThreshold Mode
Device: Adaptive DBS
Subjects for whom both aDBS modes are acceptable will receive Dual and Single Threshold aDBS
Other Name: aDBS




Primary Outcome Measures :
  1. On time without troublesome dyskinesia [ Time Frame: Change from Baseline at 1 and 2 months post-randomization ]
    Proportion of aDBS subjects with "On" time without troublesome dyskinesia exceeding the threshold (aDBS is no worse than one standard deviation less than cDBS).


Secondary Outcome Measures :
  1. Stimulation energy use [ Time Frame: Change from Baseline at 1 and 2 months post-randomization ]
    Total electrical energy delivered (TEED) for aDBS as compared with cDBS.


Other Outcome Measures:
  1. Safety (Stimulation-related AEs) [ Time Frame: Up to 45 days per mode (average of 30 days) ]
    To characterize stimulation-related adverse events

  2. Safety (SAEs, AEs and DDs) [ Time Frame: Through study completion, approximately 1.5 years ]
    To characterize serious adverse events, adverse events and device deficiencies



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

General

  1. Subject has idiopathic Parkinson's disease
  2. Subject is implanted with Percept PC (Model B35200) and Medtronic DBS leads (Model 3387 or 3389) and extensions (Model 37085 and 37086) bilaterally in the same target (physician confirmed), STN or GPi
  3. In the opinion of the investigator, the subject responds to DBS Therapy.
  4. Based on the opinion of the investigator, the subject's cDBS parameters and PD medications are stable and expected to remain stable from enrollment through the end of the aDBS Evaluation phase
  5. Subject is configured to monopolar or dual monopolar stimulation using contacts 1 and/or 2 (9 and/or 10) on at least one side
  6. Subject is willing and able to attend all study-required visits and complete the study procedures (e.g. 1-month recall questionnaires, MDS-UPDRS III)
  7. Subject has the ability to understand and provide written informed consent for participation in the study prior to the study-related procedures being conducted
  8. Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active, must be using, or agree to use, a medically-acceptable method of birth control as confirmed by the investigator

LFP Screening Inclusion Criteria

1. Subject has required Beta band (8-30 Hz) amplitude detected on either left and/or right DBS leads

Exclusion Criteria:

  1. Subject and/or caregiver is unable to utilize the patient programmer
  2. Subject has more than one lead in each hemisphere of the brain
  3. Subject has cortical leads or additional unapproved hardware implanted in the brain
  4. Subject has more than one INS
  5. At enrollment, the subject's INS has a predicted battery life of <1 year
  6. Subject has Beck Depression Inventory II (BDI-II) > 25
  7. Subject requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT)
  8. Subject has a metallic implant in the head, (eg, aneurysm clip, cochlear implant)
  9. Subject has, or plans to obtain, an implanted electrical stimulation medical device anywhere in the body (eg, cardiac pacemaker, defibrillator, spinal cord stimulator)
  10. Subject has, or plans to obtain, an implanted medication pump for the treatment of Parkinson's disease (eg, DUOPATM infusion pump) and/or portable infusion pump
  11. Based on the opinion of the investigator, the subject has an abnormal neurological examination that would preclude them from study participation
  12. Subject is breast feeding
  13. Subject is under the age of 18 years
  14. Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound the results of this study as determined by the Medtronic study team
  15. Subject is unable to use or tolerate wearable
  16. Subjects with signal artifact on all 6 aDBS sense pathways (3 each on both DBS leads)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04547712


Contacts
Layout table for location contacts
Contact: ADAPT-PD Trial Clinical Research Team 800-328-0810 rs.adapt-pdtrial@medtronic.com

Locations
Layout table for location information
United States, California
Stanford University Medical Center Recruiting
Stanford, California, United States, 94305
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32608
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
Canada, Ontario
Toronto Western Hospital Recruiting
Toronto, Ontario, Canada, M5T 25B
Sponsors and Collaborators
MedtronicNeuro
Investigators
Layout table for investigator information
Principal Investigator: Helen Bronte-Stewart, MD, MSE Stanford University
Layout table for additonal information
Responsible Party: MedtronicNeuro
ClinicalTrials.gov Identifier: NCT04547712    
Other Study ID Numbers: MDT19001
First Posted: September 14, 2020    Key Record Dates
Last Update Posted: May 5, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by MedtronicNeuro:
Deep Brain Stimulation
Parkinson's Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases